The risk of stroke in patients with dizziness


dizziness, stroke, risk factors, cerebrovas-cular diseases, Citoflavin, antioxidants, treatment of vertigo

How to Cite

Svyrydova, N. (2018). The risk of stroke in patients with dizziness. East European Journal of Neurology, (1(7), 41-47.


Primary prevention of cerebrovascular diseases is not realized, developed aspect of the program, such as dietary habits, blood pressure control, lipid concentrations, assessment of metabolic disorders - are not used as a single unit. The first step in the solving of this problem, the main recommendation of the Guide to the primary prevention of CVD which based on the fact that the risk of disease should be evaluated for all patients on the basis of a careful study of medical history, physical examination, and the results of certain lab tests. The determina-tion monitoring purposes of different risk factors with the obligatory account of individual risk factors - it is one of the advantages in identifying those who have a higher risk of developing cerebral accidents.
Proved that to the high-risk group of stroke include the patients with vertigo (other neurologic symptoms), especially men of middle and old age. Furthermore, during the imaging of the brain in most patients with dizziness have been identified unexpressed signs of a lesion of the barrel or the cerebellum, which resemble the clinical manifestations of peripheral vestibular disorders. Recent studies have shown that the dizziness is often a basic of vestibular dysfunctions that lead to the development of acute cerebral ischemia. The importance of the influence of vestibular physiology, affective neuroscience and so-cial neuroscience require a correction of manifestations of dizziness, as a factor in the risk of stroke by Citoflavin drug has a pronounced antiischemic and antioxidant effect, significantly preventing the build-up of ischemic damage to brain tissue. Drug, including in biochemical power shunt, helps to prevent unwanted effects that are typical of ischemic tissue to stabilize the work of their own antioxidant systems.


1. S. Chimirri, R. Aiello, C. Mazzitello et all. Vertigo/dizziness as a Drugs’ adverse reaction/J Pharmacol Pharmacother.- 2013.- Dec; 4(Suppl1): S104–S109.
2. Von Brevern M, Neuhauser H. Epidemiological evidence for a link between vertigo and migraine. J Vestib Res. 2011;21:299–304.
3. Арутюнов Г.П. Терапия факторов риска сердесно-сосудистых заболкваний:руководство.-М:ГЭОТАР-Медиа, 2010.-672 с.
4. Saccomano SJ. Dizziness, vertigo and presyncope: What's the difference? Nurse Pract. 2012;37:46–52.
5. Chawla N, Olshaker JS. Diagnosis and management of dizziness and vertigo. Med Clin North Am. 2006;90:291–304.
6. Neuhauser HK, Lempert T. Vertigo: Epidemiologic aspects. Semin Neurol. 2009;29:473–81.
7. Brandt T. 2nd ed. London: Springer-Verlag; 2003. Vertigo: Its multisensory Syndromes.
8. Brandt T, Dieterich M, Strupp M. 5th ed. London: Springer-Verlag; 2009. Vertigo and dizziness: Common complaints.
9. Krishna Das KV. 4th ed. New Delhi, India: Jaypee; 2013. Clinical Medicine: A textbook of Clinical Mehods and Laboratory Investigations.
10. Thompson TL, Amedee R. Vertigo: A review of common peripheral and central vestibular disorders. Ochsner J. 2009;9:20–6.
11. Solomon D. Distinguishing and treating causes of central vertigo. Otolaryngol Clin North Am. 2000;33:579–601.
12. Choi KD, Lee H, Kim JS. Vertigo in brainstem and cerebellar strokes. Curr Opin Neurol. 2013;26:90–5.
13. Smouha E. Inner ear disorders. NeuroRehabilitation. 2013;32:455–62.
14. Schneider JI, Olshaker JS. Vertigo, vertebrobasilar disease, and posterior circulation ischemic stroke. Emerg Med Clin North Am. 2012;30:681–93.
15. Lee AT. Diagnosing the cause of vertigo: A practical approach. Hong Kong Med J. 2012;18:327–32.
16. Post RE, Dickerson LM. Dizziness: A diagnostic approach. Am Fam Psysician. 2010;82:361–9.
17. Kim YH, Kim KS, Kim KJ, Choi H, Choi JS, Hwang IK. Recurrence of vertigo in patients with vestibular neuritis. Acta Otolaryngol. 2011;131:1172–7.
18. Shin JE, Kim CH, Park HJ. Vestibular abnormality in patients with Meniere's disease and migrainous vertigo. Acta Otolaryngol. 2013;133:154–8.
19. Son EJ, Bang JH, Kang JG. Anterior inferior cerebellar artery infarction presenting with sudden hearing loss and vertigo. Laryngoscope. 2007;117:556–8.
20. Shah H, Mukherjee S. Psychogenic Vertigo. Otorhinolaryngol Clin Int J. 2012;4:77–80.
21. Kevin A. Kerber, Devin L. Brown, Lynda D. Lisabeth, Melinda A. Smith, Lewis B. Morgenstern. Stroke Among Patients With Dizziness, Vertigo, and Imbalance in the Emergency Department: A Population-Based Study/Stroke.- 2006.- Oct; 37(10): 2484–2487.
22. Toshiaki Yamanaka, Takehiko Fukuda, Shiho Shirota et all. The Prevalence and Characteristics of Metabolic Syndrome in Patients with Vertigo/ PLoS One. 2013; 8(12): p.801-76.
23. Agrawal Y, Carey JP, Della Santina CC, Schubert MC, Minor LB (2009) Disorders of balance and vestibular function in US adults: data from the National Health and Nutrition Examination Survey, 2001–2004. Arch Intern Med 169: 938–944
24. Saadah H (1993) Vestibular vertigo associated with hyperlipidemia: response to antilipidemic therapy. Arch Intern Med 153: 1846–1849
25. Pulec JL, Pulec MB, Mendoza I (1997) Progressive sensorineural hearing loss, subjective tinnitus and vertigo caused by elevated blood lipids. Ear Nose Throat J 10: 716–720
26. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, et al. (2001) Cardiovascular Morbidity and Mortality Associated with the Metabolic Syndrome. Diabetes Care 24: 683–689
27. Galassi A, Reynolds K, He J (2006) Metabolic syndrome and risk of cardiovascular disease: a meta-analysis. Am J Med 119: 812–819
28. Goldstein LB, Bushnell CD, Adams RJ, Appel LJ, Braun LT, et al. (2011) Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 42: 517–584
29. Cianfrone G, Pentangelo D, Cianfrone E, Mazzei F, Turchetta R, Orlando MP, et al. Pharmacological drugs inducing ototoxicity, vestibular symptoms and tinnitus: A reasoned and updated guide. Eur Rev Med Pharmacol Sci. 2011;15:601–36.
30. Cianfrone G, Pace M, Turchetta R, Cianfrone F, Altissimi G. An update guide on drugs inducing ototoxicity, tinnitus and vertigo. Acta Otorhinolaryngol Ital. 2005;25(5 Suppl 81):3–31.
31. Labuguen RH. Initial evaluation of vertigo. Am Fam Physician. 2006;73:244–51.
32. Vohora D, Saraogi P, Yazdani MA, Bhowmik M, Khanam R, Pillai KK. Recent avances in adjunctive therapy for epilepsy: Focus on sodium canne blockers as third-generation antiepileptic drugs. Drug Today (Barc) 2010;46:265–77.
33. Beydoun A, D’Souza J, Hebert D, Doty P. Lacosamide: Pharmacology, mechanisms of action and pooled efficacy and safety data in partial-onset seizures. Expert Rev Neurother. 2009;9:33–42.
34. Jenner P, Pratt JA, Marsden CD. Mechanism of action of clonazepam in myoclonus in relation to effects on GABA and 5-HT. Adv Neurol. 1986;43:629–43.
35. Shields DL. Calcium channel blockers as initial therapeutic agents in hypertension: Relationship to incident heart failure. Biol Res Nurs. 2013 Jul 16;
36. Forni V, Wuerzner G, Pruijm M, Burnier M. Long-term use and tolerability of irbesartan for control of hypertension. Integr Blood Press Control. 2011;4:17–26.
37. Greathouse MK, Weir MR. The role of ARBs alone or with HCTZ in the treatment of hypertension and prevention of cardiovascular and renal complications. Postgrad Med. 2012;124:40–52.
38. Benjamin S, Doraiswamy PM. Review of the use of mirtazapine in the treatment of depression. Expert Opin Pharmacother. 2011;12:1623–32.
39. Fitzgerald KT, Bronstein AC. Selective serotonin reuptake inhibitor exposure. Top Companion Anim Med. 2013;28:13–7.
40. Lode H, Borner K, Koeppe P. Pharmacodynamics of fluoroquinolones. Clin Infect Dis. 1998;27:33–9.
41. Weber DJ, Tolkoff-Rubin NE, Rubin RH. Amoxicillin and potassium clavulanate: An antibiotic combination. Mechanism of action, pharmacokinetics, antimicrobial spectrum, clinical efficacy and adverse effects. Pharmacoterapy. 1984;4:122–36.
42. Osman NI, Chapple CR, Cruz F, Desgrandchamps F, Llorente C, Montorsi F. Silodosin: A new subtype selective alpha-1 antagonist for the treatment of lower urinary tract symptoms in patients with benign prostatic hyperplasia. Expert Opin Pharmacother. 2012;13:2085–96.
43. Horn J. The proton-pump inhibitors: Similarities and differences. Clin Ther. 2000;22:266–80.
44. Radhofer-Welte S, Rabasseda X. Lornoxicam, a new potent NSAID with an improved tolerability profile. Drugs Today (Barc) 2000;36:55–76
45. Hirose T, Uwahodo Y, Yamada S, Miwa T, Kikuchi T, Kitagawa H, et al. Mechanism of action of aripiprazole predicts clinical efficacy and a favourable side-effect profile. J Psychopharmacol. 2004;18:375–83.
46. Bentuè-Ferre D, Arvieux C, Tribut O, Ruffault A, Bellissant E. Clinical pharmacology, efficacy and safety of atazanavir: A review. Expert Opin Drug Metab Toxicol. 2009;5:1455–68
47. Федин А., Румянцева С., Пирадов М., Скоромец А.и др. Клиническая эффективность «Цитофлавина» у больных с хронической ишемией головного мозга (многоцентровое плацебо-контролируемое рандомизированное исследование)/ Неврология, практическая медицина.-2009-№ 06 (09).- С. 32-39
48. Румянцева С.А., Ступин В.А., Афанасьев В.В., Силина Е.В. Алгоритмы и схемы терапии заболеваний часто встречающихся в клинической практике (Краткое практическое руководство для врачей разных специ-альностей). — М-С-Пб.: Международная издательская группа «Медицинская книга», 2012. — 432 стр.